Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny

Executive Summary

So far, most of the attention on drug price increases has focused on Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. But Mylan NV soon could be in the bull's-eye of payers and lawmakers after hiking the prices of 24 of the firm's products by more than 20% in the past six month, with seven of those medicines' costs spiking more than 100%, Wells Fargo analyst David Maris said in a new report.

Advertisement

Related Content

Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Life's A Musical For Martin Shkreli
Beware The 'Pitchforks,' Pharma
Valeant: Another Fine Mess
It Was Shkreli's Show, But Pharma Was On Trial
Antitrust Trouble For Turing? NY Opens Probe

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel